MX2019000381A - Formulacion para la administracion de arn. - Google Patents
Formulacion para la administracion de arn.Info
- Publication number
- MX2019000381A MX2019000381A MX2019000381A MX2019000381A MX2019000381A MX 2019000381 A MX2019000381 A MX 2019000381A MX 2019000381 A MX2019000381 A MX 2019000381A MX 2019000381 A MX2019000381 A MX 2019000381A MX 2019000381 A MX2019000381 A MX 2019000381A
- Authority
- MX
- Mexico
- Prior art keywords
- rna
- relates
- present
- administration
- formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16171—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Physics & Mathematics (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Inorganic Chemistry (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se relaciona a composiciones que comprenden formulaciones de polyplex para entrega de ARN a un órgano objetivo o una célula objetivo después de administración parenteral, en particular después de administración intramuscular. Más precisamente, la presente invención se relaciona a formulaciones para administración de ARN tal como ARN autorreplicante, en particular por inyección intramuscular. A mayor detalle, las formulaciones comprenden partículas de polyplex de ARN de hebra sencilla y una polialquilenimina. El ARN puede codificar una proteína de interés, tal como una proteína farmacéuticamente activa. Además, la presente invención se relaciona a productos farmacéuticos, que comprenden dichas formulaciones de polyplex de ARN para aplicación parenteral a humanos o animales. La presente invención se relaciona también a la fabricación de tales productos farmacéuticos, que comprende, opcionalmente, etapas de filtración estéril, congelación y deshidratación.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2016/066930 WO2018010815A1 (en) | 2016-07-15 | 2016-07-15 | Formulation for administration of rna |
PCT/EP2017/067887 WO2018011406A1 (en) | 2016-07-15 | 2017-07-14 | Formulation for administration of rna |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019000381A true MX2019000381A (es) | 2019-05-23 |
Family
ID=56413679
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019000381A MX2019000381A (es) | 2016-07-15 | 2017-07-14 | Formulacion para la administracion de arn. |
Country Status (11)
Country | Link |
---|---|
US (2) | US11318195B2 (es) |
EP (2) | EP3484445B1 (es) |
JP (2) | JP7139307B2 (es) |
KR (1) | KR102432434B1 (es) |
CN (1) | CN109562059A (es) |
AU (1) | AU2017297822B2 (es) |
CA (1) | CA3027148A1 (es) |
ES (1) | ES2877160T3 (es) |
MX (1) | MX2019000381A (es) |
RU (2) | RU2021108337A (es) |
WO (2) | WO2018010815A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2019207761A1 (en) * | 2018-01-11 | 2020-07-02 | BioNTech SE | Formulation for administration of RNA |
CN112153985B (zh) * | 2018-04-25 | 2024-03-01 | 埃泽瑞斯公司 | 用于颗粒制剂的防冻剂 |
EP3826608A1 (en) * | 2018-07-23 | 2021-06-02 | Translate Bio, Inc. | Dry power formulations for messenger rna |
EP4103228A1 (en) | 2020-02-13 | 2022-12-21 | Institut Pasteur | Nucleic acid vaccine against the sars-cov-2 coronavirus |
AU2021233816A1 (en) | 2020-03-09 | 2022-10-06 | Arcturus Therapeutics, Inc. | Coronavirus vaccine compositions and methods |
AU2021252164A1 (en) | 2020-04-09 | 2022-12-15 | Finncure Oy | Mimetic nanoparticles for preventing the spreading and lowering the infection rate of novel coronaviruses |
EP3984527A1 (en) * | 2020-10-13 | 2022-04-20 | Ludwig-Maximilians-Universität München | Nano-in-micro encapsulated sirna dry powder, method for producing the same and use of a powder formulation as a pharmaceutical dosage form, in particular for pulmonary delivery |
JP2024518335A (ja) | 2021-04-26 | 2024-05-01 | アンスティチュ パスツール | SARS-CoV-2に対するヒト中和モノクローナル抗体、及びそれらの使用 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2372306A1 (en) | 1999-03-09 | 2000-09-14 | Large Scale Biology Corp. | Multiple component rna vector system for expression of foreign sequences |
CN1305932C (zh) * | 2002-02-22 | 2007-03-21 | 植入疗法公司 | 碳水化合物修饰的聚合物、其组合物及其应用 |
EP1592412A1 (en) * | 2003-01-31 | 2005-11-09 | Novartis AG | Down-regulation of target-gene with pei/single-stranded oligoribonucleotide complexes |
US20070231392A1 (en) * | 2006-01-23 | 2007-10-04 | Ernst Wagner | CHEMICALLY MODIFIED POLYCATION POLYMER FOR siRNA DELIVERY |
WO2011069529A1 (en) | 2009-12-09 | 2011-06-16 | Curevac Gmbh | Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids |
WO2013096709A2 (en) * | 2011-12-21 | 2013-06-27 | modeRNA Therapeutics | Methods of increasing the viability or longevity of an organ or organ explant |
DK2858677T3 (da) | 2012-06-08 | 2020-08-31 | Ethris Gmbh | Pulmonær levering af messenger rna |
WO2014071963A1 (en) | 2012-11-09 | 2014-05-15 | Biontech Ag | Method for cellular rna expression |
AU2014310935B2 (en) * | 2013-08-21 | 2019-11-21 | CureVac SE | Combination vaccine |
WO2015057847A1 (en) * | 2013-10-16 | 2015-04-23 | Cerulean Pharma Inc. | Conjugates, particles, compositions, and related methods |
EP3034539A1 (en) | 2014-12-19 | 2016-06-22 | Ethris GmbH | Compositions for introducing nucleic acid into cells |
-
2016
- 2016-07-15 WO PCT/EP2016/066930 patent/WO2018010815A1/en active Application Filing
-
2017
- 2017-07-14 EP EP17743293.7A patent/EP3484445B1/en active Active
- 2017-07-14 CA CA3027148A patent/CA3027148A1/en active Pending
- 2017-07-14 US US16/314,719 patent/US11318195B2/en active Active
- 2017-07-14 AU AU2017297822A patent/AU2017297822B2/en active Active
- 2017-07-14 EP EP21165536.0A patent/EP3881827A1/en active Pending
- 2017-07-14 ES ES17743293T patent/ES2877160T3/es active Active
- 2017-07-14 RU RU2021108337A patent/RU2021108337A/ru unknown
- 2017-07-14 RU RU2019103434A patent/RU2746118C2/ru active
- 2017-07-14 CN CN201780043331.5A patent/CN109562059A/zh active Pending
- 2017-07-14 JP JP2019501687A patent/JP7139307B2/ja active Active
- 2017-07-14 KR KR1020197001180A patent/KR102432434B1/ko active IP Right Grant
- 2017-07-14 MX MX2019000381A patent/MX2019000381A/es unknown
- 2017-07-14 WO PCT/EP2017/067887 patent/WO2018011406A1/en unknown
-
2022
- 2022-04-11 US US17/717,645 patent/US20220313811A1/en active Pending
- 2022-09-07 JP JP2022142231A patent/JP2022174191A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
BR112018077163A2 (pt) | 2019-04-30 |
BR112018077163A8 (pt) | 2022-07-26 |
US20190321458A1 (en) | 2019-10-24 |
JP2022174191A (ja) | 2022-11-22 |
US11318195B2 (en) | 2022-05-03 |
JP7139307B2 (ja) | 2022-09-20 |
EP3881827A1 (en) | 2021-09-22 |
AU2017297822B2 (en) | 2022-12-22 |
EP3484445A1 (en) | 2019-05-22 |
WO2018010815A1 (en) | 2018-01-18 |
WO2018011406A1 (en) | 2018-01-18 |
AU2017297822A1 (en) | 2019-01-03 |
CN109562059A (zh) | 2019-04-02 |
JP2019527685A (ja) | 2019-10-03 |
EP3484445B1 (en) | 2021-03-31 |
CA3027148A1 (en) | 2018-01-18 |
KR102432434B1 (ko) | 2022-08-16 |
ES2877160T3 (es) | 2021-11-16 |
RU2019103434A3 (es) | 2020-08-17 |
RU2019103434A (ru) | 2020-08-17 |
US20220313811A1 (en) | 2022-10-06 |
RU2021108337A (ru) | 2021-04-09 |
KR20190029588A (ko) | 2019-03-20 |
RU2746118C2 (ru) | 2021-04-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019000381A (es) | Formulacion para la administracion de arn. | |
WO2017044894A3 (en) | Cartilage-homing peptides | |
EP4332576A3 (en) | Synergistic enhancement of the delivery of nucleic acids via blended formulations | |
MX2020003413A (es) | Preparacion y almacenamiento de formulaciones liposomales de arn adecuadas para terapia. | |
MX2018002627A (es) | Metodo de cristalizacion y biodisponibilidad. | |
WO2016170348A3 (en) | Sarna compositions and methods of use | |
MX2020007477A (es) | Formulacion para la administracion de arn. | |
WO2012135805A3 (en) | Delivery and formulation of engineered nucleic acids | |
WO2014205317A3 (en) | Cyclic peptides as protein targeting agents | |
WO2015018380A3 (en) | Therapeutic nanoparticles and the preparation methods thereof | |
WO2012168430A3 (en) | Polypeptides | |
MX2017015879A (es) | Composiciones de hidroxipropil beta-ciclodextrina y metodos. | |
WO2017009843A3 (en) | Compositions, articles of manufacture and methods for treating cancer | |
WO2015044337A3 (en) | Dry formulations of vaccines that are room temperature stable | |
SG11202001161YA (en) | Method of producing pharmaceutical compositions comprising immunogenic chikungunya virus chikv-delta5nsp3 | |
WO2011140595A3 (en) | Immunostimulatory and vaccine compositions | |
AU2017262586A1 (en) | Improved drug formulations | |
EP3539951A4 (en) | NOVEL PYRIMIDINE COMPOUND, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AS AN ACTIVE INGREDIENT FOR THE PREVENTION OR TREATMENT OF CANCER AND INFLAMMATORY DISEASES | |
MX2018012618A (es) | Composiciones farmaceuticas orales de mesalazina. | |
PH12016501519B1 (en) | Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions | |
NZ728401A (en) | High purity oritavancin and method of producing same | |
MX2016001422A (es) | Composicion farmaceutica de fingolimod. | |
EP3352750A4 (en) | Cyclohexene derivative, preparation method thereof, and pharmaceutical composition for preventing or treating metabolic disease comprising the same as active ingredient | |
WO2017093810A3 (en) | Composition for intraoral delivery of biologically active peptides and proteins | |
EA201490032A1 (ru) | Лиофилизированные препараты fgf-18 |